A case report of immune checkpoint inhibitor‐related myositis and cholangitis induced by pembrolizumab
Key Clinical Message Rare but severe, immune‐related adverse events such as myositis and sclerosing cholangitis can occur with immune checkpoint inhibitors in lung cancer treatment. This case report highlights their co‐occurrence after pembrolizumab treatment, indicating the need for vigilance and m...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2024-07-01
|
| Edice: | Clinical Case Reports |
| Témata: | |
| On-line přístup: | https://doi.org/10.1002/ccr3.9153 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|